Taysha Gene Therapies (TSHA) Enterprise Value (2020 - 2026)
Taysha Gene Therapies (TSHA) reported Enterprise Value of -$277.0 million for Q1 2026, down 136.71% on a YoY basis from $754.7 million in Q1 2025, and up 13.48% sequentially from -$320.2 million in Q4 2025.
Taysha Gene Therapies (TSHA) Enterprise Value (2020 - 2026) Analysis & Trends
Taysha Gene Therapies (TSHA) has 7 years of Enterprise Value data on file, last reported at -$277.0 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value fell 136.71% year-over-year to -$277.0 million; the trailing twelve-month figure through Mar 2026 stood at -$277.0 million (down 136.71% YoY), and the FY2025 full-year result was -$320.2 million, down 129.57% from the prior year.
- Enterprise Value advanced to -$277.0 million in Q1 2026, from -$320.2 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$36.9 million in Q3 2022 to a low of -$320.2 million in Q4 2025.
- A 5-year average of -$158.8 million and a median of -$141.9 million in 2023 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value surged 80.7% in 2022 and tumbled 344.68% in 2023, its largest moves.
- Tracing TSHA's Enterprise Value over 5 years: stood at -$36.9 million in 2022, then plunged by 290.84% to -$144.4 million in 2023, then gained by 3.4% to -$139.5 million in 2024, then plunged by 129.57% to -$320.2 million in 2025, then rose by 13.48% to -$277.0 million in 2026.
- Business Quant data shows TSHA's Enterprise Value at -$277.0 million in Q1 2026, -$320.2 million in Q4 2025, and -$297.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Taysha Gene Therapies | 2.14 Bn | 2.14 Bn | - | -277.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -277.05 Mn |
| Dec 31, 2025 | -320.22 Mn |
| Sep 30, 2025 | -297.79 Mn |
| Jun 30, 2025 | -313.21 Mn |
| Mar 31, 2025 | -117.04 Mn |
| Dec 31, 2024 | -139.49 Mn |
| Sep 30, 2024 | -158.14 Mn |
| Jun 30, 2024 | -173.19 Mn |
| Mar 31, 2024 | -124.43 Mn |
| Dec 31, 2023 | -144.39 Mn |
| Sep 30, 2023 | -164.28 Mn |
| Jun 30, 2023 | -45.08 Mn |
| Mar 31, 2023 | -63.43 Mn |
| Sep 30, 2022 | -36.94 Mn |
| Jun 30, 2022 | -66.24 Mn |
| Mar 31, 2022 | -99.27 Mn |
| Dec 31, 2021 | -151.74 Mn |
| Sep 30, 2021 | -191.41 Mn |
| Jun 30, 2021 | -197.37 Mn |
| Mar 31, 2021 | -228.68 Mn |